TrialNeuro-oncology2019
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Wolfgang Wick et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
99 papers cite itlatest 60 shown
this paperpooled ittrialcites it